Biological age measured by DNA methylation clocks and frailty: a systematic review and meta-analysis.

作者：Jianhua Tay, D. Barros, Weilan Wang, V. Wazny, A. Maier · 发表于：The Lancet Healthy Longevity · 年份：2025 · DOI：10.1016/j.lanhl.2025.100773 · 被引用次数：10 · 研究领域：Medicine

BACKGROUND Frailty is an age-related condition characterised by multisystem physiological decline, which increases vulnerability to adverse outcomes. Biomarkers of ageing might identify individuals at risk and enable early interventions. This systematic review and meta-analysis aimed to examine cross-sectional and longitudinal associations between DNA methylation-based biological age metrics (eg, DNA methylation age, epigenetic-age acceleration [EAA], and age deviation) and frailty. METHODS In a systematic search of six databases (Embase, Cochrane Central Register of Controlled Trials, PubMed, Ovid, Scopus, and Web of Science) from Jan 1, 2011, to June 6, 2025, we identified population-based cohort studies reporting associations between DNA methylation age, EAA, or age deviation and frailty from general or disease-specific populations with a control group. Risk of bias was assessed using an adapted Newcastle-Ottawa Scale. Random-effects meta-analyses with Hartung-Knapp adjustments were performed on standardised β coefficients and SEs. Publication bias, influence, and sensitivity analyses were conducted. FINDINGS From 34 437 records screened, 24 studies met the inclusion criteria (17 cross-sectional studies, one longitudinal study, and six studies that were both cross-sectional and longitudinal), encompassing 28 325 participants (14 757 [52·1%] female; median of mean age 65·2 years [IQR 62·2-69·4]). DNA methylation age and age deviation showed no association with frailty. ...